Company intelligence
Climb Bio
Committed to developing better treatments for patients with immune-mediated diseases
About Climb Bio
Immune-mediated diseases impact 1:7 people and are increasing in prevalence worldwide. They occur when the immune system mistakenly attacks the tissues of the body and can result in permanent organ damage or even death. Despite advances in treatment, many patients with immune-mediated diseases suffer from poor outcomes when their disease cannot be controlled with available therapies. At Climb Bio, we believe that we can impact the pathways that cause immune-mediated diseases to give patients precious time free of disease.
Verified activity
Signals from Climb Bio
6 published signals
Research & Knowledge
Climb Bio will share initial Phase 1 data for its investigational anti-APRIL mAb CLYM116 in development for IgAN at the R&D Spotlight Event on September 3.
Reported by Climb Bio
Research & Knowledge
Climb Bio shared additional data from its Phase 1 trials in Australia and China for the R&D Spotlight CLYM116 Initial Phase 1 Data.
Reported by Climb Bio
Research & Knowledge
Climb Bio shared Budoprutug SLE initial data Phase 1b data for the Morgan Stanley event.
Reported by Climb Bio
Research & Knowledge
Climb Bio shared Budoprutug PrisMN Phase 2 initial data for the Wells Fargo Healthcare Conference.
Reported by Climb Bio
Research & Knowledge
Climb Bio shared Budoprutug ITP additional Phase 1b data for the Trail Ahead event.
Reported by Climb Bio
Presence & Recognition
Climb Bio supported the Platelet Disorder Support Association - PDSA by lighting up monuments and landmarks in purple between now and September 25 to raise awareness of immune thrombocytopenia and make the community more visible.
Reported by Climb Bio